Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02264990




Registration number
NCT02264990
Ethics application status
Date submitted
9/10/2014
Date registered
15/10/2014
Date last updated
26/02/2021

Titles & IDs
Public title
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
Scientific title
A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
Secondary ID [1] 0 0
2014-002565-30
Secondary ID [2] 0 0
M14-359
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-squamous Non-small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Carboplatin
Treatment: Drugs - Cisplatin
Treatment: Drugs - Veliparib
Treatment: Drugs - Pemetrexed

Experimental: Veliparib + Carboplatin + Paclitaxel - Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.

After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.

Active comparator: Investigator's Choice Chemotherapy - Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:

* Carboplatin AUC 6 mg/mL\*min + paclitaxel 200 mg/m²
* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²
* Carboplatin AUC 6 or AUC 5 mg/mL\*min + pemetrexed 500 mg/m²

After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.


Treatment: Drugs: Paclitaxel
Administered by Intravenous infusion on Day 1 of each 21-day cycle

Treatment: Drugs: Carboplatin
Administered by Intravenous infusion on Day 1 of each 21-day cycle

Treatment: Drugs: Cisplatin
Administered by Intravenous infusion on Day 1 of each 21-day cycle

Treatment: Drugs: Veliparib
Oral capsule, administered twice daily for 7 days in each 21-day cycle

Treatment: Drugs: Pemetrexed
Administered by Intravenous infusion on Day 1 of each 21-day cycle
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup
Timepoint [1] 0 0
From randomization up to the data cut-off date of 15 July 2019; median follow-up time was 44.5 and 45.3 months in LSP+ participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.
Secondary outcome [1] 0 0
Progression Free Survival (PFS) in the Lung Subtype Panel Positive Subgroup
Timepoint [1] 0 0
From randomization up to the data cut-off date of 15 July 2019; the median follow-up time was 44.5 and 45.3 months in LSP+ participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.
Secondary outcome [2] 0 0
Objective Response Rate (ORR) in the Lung Subtype Panel Positive Subgroup
Timepoint [2] 0 0
Assessed on Day 1 of Cycles 3 and 5 then every 9 weeks for 1 year or until maintenance therapy was discontinued, then every 12 weeks until radiographic progression or death; median time on follow-up was 5.2 and 6.3 months in each group, respectively.
Secondary outcome [3] 0 0
Overall Survival in All Participants
Timepoint [3] 0 0
From randomization up to the data cut-off date of 15 July 2019; the median OS follow-up time was 45.4 and 44.6 months in all participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.
Secondary outcome [4] 0 0
Progression Free Survival (PFS) in All Participants
Timepoint [4] 0 0
From randomization up to the data cut-off date of 15 July 2019; the median follow-up time was 45.4 and 44.6 months in all participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.
Secondary outcome [5] 0 0
Objective Response Rate (ORR) in All Participants
Timepoint [5] 0 0
Assessed on Day 1 of Cycles 3 and 5 then every 9 weeks for 1 year or until maintenance therapy was discontinued, then every 12 weeks until radiographic progression or death; median time on follow-up was 6.7 and 5.9 months in each group, respectively.

Eligibility
Key inclusion criteria
* Subject must be = 18 years of age with life expectancy > 12 weeks.
* Subject must have cytologically or histologically confirmed advanced or metastatic non-squamous NSCLC and are current or former smokers.
* Subject must have NSCLC that is not amenable to surgical resection or radiation with curative intent at time of screening.
* Subject must have at least 1 unidimensional measurable NSCLC lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
* Subject has a known hypersensitivity to platinum compounds.
* Subject has peripheral neuropathy = grade 2.
* Subject has squamous NSCLC, or an untreated known epidermal growth factor receptor (EGFR) mutation of exon 19 deletion or L858R mutation in exon 21, or a known anaplastic lymphoma kinase (ALK) gene rearrangement.
* Subject has received prior cytotoxic chemotherapy or chemoradiotherapy for NSCLC.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/09/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
21/02/2020
Sample size
Target
Accrual to date
Final
595
Recruitment in Australia
Recruitment state(s)
NSW,SA,TAS
Recruitment hospital [1] 0 0
St George Hospital /ID# 132481 - Kogarah
Recruitment hospital [2] 0 0
Southern Medical Day Care Ctr /ID# 132482 - Wollongong
Recruitment hospital [3] 0 0
Flinders Centre for Innovation /ID# 134288 - Bedford Park
Recruitment hospital [4] 0 0
Royal Hobart Hospital /ID# 132477 - Hobart
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
2500 - Wollongong
Recruitment postcode(s) [3] 0 0
5042 - Bedford Park
Recruitment postcode(s) [4] 0 0
7000 - Hobart
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Oklahoma
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Tennessee
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
Argentina
State/province [17] 0 0
Berazategui, Buenos Aires
Country [18] 0 0
Argentina
State/province [18] 0 0
Pergamino
Country [19] 0 0
Argentina
State/province [19] 0 0
Rosario, Santa FE
Country [20] 0 0
Canada
State/province [20] 0 0
Nova Scotia
Country [21] 0 0
Canada
State/province [21] 0 0
Ontario
Country [22] 0 0
Canada
State/province [22] 0 0
Quebec
Country [23] 0 0
Czechia
State/province [23] 0 0
Liberec
Country [24] 0 0
Czechia
State/province [24] 0 0
Ostrava
Country [25] 0 0
Czechia
State/province [25] 0 0
Pardubice
Country [26] 0 0
Czechia
State/province [26] 0 0
Prague
Country [27] 0 0
Denmark
State/province [27] 0 0
Syddanmark
Country [28] 0 0
Finland
State/province [28] 0 0
Pori
Country [29] 0 0
Finland
State/province [29] 0 0
Vaasa
Country [30] 0 0
Germany
State/province [30] 0 0
Berlin
Country [31] 0 0
Germany
State/province [31] 0 0
Grosshansdorf
Country [32] 0 0
Germany
State/province [32] 0 0
Hamburg
Country [33] 0 0
Germany
State/province [33] 0 0
Löwenstein
Country [34] 0 0
Hungary
State/province [34] 0 0
Borsod-Abauj-Zemplen
Country [35] 0 0
Hungary
State/province [35] 0 0
Budapest
Country [36] 0 0
Hungary
State/province [36] 0 0
Debrecen
Country [37] 0 0
Hungary
State/province [37] 0 0
Edelény
Country [38] 0 0
Hungary
State/province [38] 0 0
Farkasgyepu
Country [39] 0 0
Hungary
State/province [39] 0 0
Gyor
Country [40] 0 0
Hungary
State/province [40] 0 0
Kékesteto
Country [41] 0 0
Israel
State/province [41] 0 0
Be'er Ya'akov
Country [42] 0 0
Israel
State/province [42] 0 0
Jerusalem
Country [43] 0 0
Israel
State/province [43] 0 0
Kfar Saba
Country [44] 0 0
Israel
State/province [44] 0 0
Ramat Gan
Country [45] 0 0
Japan
State/province [45] 0 0
Aichi
Country [46] 0 0
Japan
State/province [46] 0 0
Fukuoka
Country [47] 0 0
Japan
State/province [47] 0 0
Hokkaido
Country [48] 0 0
Japan
State/province [48] 0 0
Kanagawa
Country [49] 0 0
Japan
State/province [49] 0 0
Miyagi
Country [50] 0 0
Japan
State/province [50] 0 0
Osaka
Country [51] 0 0
Japan
State/province [51] 0 0
Tokyo
Country [52] 0 0
Japan
State/province [52] 0 0
Yamaguchi
Country [53] 0 0
Japan
State/province [53] 0 0
Hiroshima
Country [54] 0 0
Japan
State/province [54] 0 0
Kishiwada
Country [55] 0 0
Korea, Republic of
State/province [55] 0 0
Busan Gwang Yeogsi
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Gyeonggido
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Incheon Gwang Yeogsi
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Jeonranamdo
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Seoul Teugbyeolsi
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Cheongju
Country [61] 0 0
Netherlands
State/province [61] 0 0
Amsterdam
Country [62] 0 0
Netherlands
State/province [62] 0 0
Eindhoven
Country [63] 0 0
Netherlands
State/province [63] 0 0
Harderwijk
Country [64] 0 0
Netherlands
State/province [64] 0 0
Nieuwegein
Country [65] 0 0
Netherlands
State/province [65] 0 0
S Hertogenbosch
Country [66] 0 0
New Zealand
State/province [66] 0 0
Christchurch
Country [67] 0 0
New Zealand
State/province [67] 0 0
Wellington
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Moskva
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Sverdlovskaya Oblast
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Arkhangelsk
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Balashikha
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Belgorod
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Moscow
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Murmansk
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Orenburg
Country [76] 0 0
Russian Federation
State/province [76] 0 0
Sankt-Peterburg
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Saransk
Country [78] 0 0
Russian Federation
State/province [78] 0 0
St. Petersburg
Country [79] 0 0
South Africa
State/province [79] 0 0
Eastern Cape
Country [80] 0 0
South Africa
State/province [80] 0 0
Gauteng
Country [81] 0 0
South Africa
State/province [81] 0 0
Kwazulu-Natal
Country [82] 0 0
South Africa
State/province [82] 0 0
Western Cape
Country [83] 0 0
South Africa
State/province [83] 0 0
Johannesburg
Country [84] 0 0
Spain
State/province [84] 0 0
Barcelona
Country [85] 0 0
Spain
State/province [85] 0 0
Alcorcon
Country [86] 0 0
Spain
State/province [86] 0 0
Alicante
Country [87] 0 0
Spain
State/province [87] 0 0
Madrid
Country [88] 0 0
Spain
State/province [88] 0 0
Valencia
Country [89] 0 0
Taiwan
State/province [89] 0 0
Taichung
Country [90] 0 0
Taiwan
State/province [90] 0 0
Dalin Township
Country [91] 0 0
Taiwan
State/province [91] 0 0
Taipei City
Country [92] 0 0
Turkey
State/province [92] 0 0
Ankara
Country [93] 0 0
Turkey
State/province [93] 0 0
Bursa
Country [94] 0 0
Turkey
State/province [94] 0 0
Diyarbakir
Country [95] 0 0
Turkey
State/province [95] 0 0
Gaziantep
Country [96] 0 0
Turkey
State/province [96] 0 0
Izmir
Country [97] 0 0
Turkey
State/province [97] 0 0
Malatya
Country [98] 0 0
United Kingdom
State/province [98] 0 0
England
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Gloucestershire
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Norfolk
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Bath
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Belfast
Country [103] 0 0
United Kingdom
State/province [103] 0 0
Birmingham
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Blackburn
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Colchester
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Cottingham
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Doncaster
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Great Yarmouth
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Gwent
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Huddersfield
Country [111] 0 0
United Kingdom
State/province [111] 0 0
London
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Newcastle Upon Tyne
Country [113] 0 0
United Kingdom
State/province [113] 0 0
York

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.
Trial website
https://clinicaltrials.gov/study/NCT02264990
Trial related presentations / publications
Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T, Lee KH, Nakagawa K, Hansen O, Biesma B, Kundu MG, Dunbar M, He L, Ansell P, Sehgal V, Huang X, Glasgow J, Bach BA. Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 May;23(3):214-225. doi: 10.1016/j.cllc.2022.01.005. Epub 2022 Feb 4.
Public notes

Contacts
Principal investigator
Name 0 0
AbbVie Inc.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02264990